The purpose of this pilot study was to describe short and long-term changes in cognitive function and quality of life in patients with melanoma receiving interferon (IFN)-2b. This study used a three-group, repeated measures design in which cognitive function and quality of life were evaluated prior to initiation of treatment at 3-month intervals during treatment and 3 months following the completion of treatment. The sample consisted of 16 adults with Stage II or III melanoma, randomized to one of three treatment groups. Participants in Arm A received high-dose IFN-2b, those in Arm B received low-dose IFN•-2b, and those in Arm C received no therapy (control). No significant changes in cognitive function were detected. In participants in ArmA, there was a significant deterioration in the physical well-being dimension of quality of life from baseline to 3 months after beginning therapy.
Get full access to this article
View all access options for this article.
References
1.
Adams, F.
, Quesada, J. R., & Gutterman, J. U. (1984). Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. Journal of the American Medical Association, 252(7), 938-941.
2.
Boone, D. E.
(1992). Reliability of the WAIS-R with psychiatric inpatients. Journal of Clinical Psychiatry, 48(11), 72-76.
3.
Bornstein, R. A.
(1987). Normative data on selected neuropsychological data from a nonclinical sample. Perceptual and Motor Skills, 41, 651-659.
4.
Cella, D. F.
, Tulsky, D. S., Gray, G., Sarafin, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., Brannon, J., Eckberg, K., Lloyd, S., Purl, S., Blendowski, C., Goodman, M., et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
5.
Denicoff, K. D.
, Rubinow, D. R., Papa, M. Z., Simpson, C., Seipp, C. A., Lotze, M. T., Chang, A. E., Rosenstein, D., & Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells. Annals of Internal Medicine, 107, 293-300.
6.
Ferrans, C. E.
(1990). Development of a quality of life index for patients with cancer. Oncology Nursing Forum, 17(Suppl. 3), 15-21.
7.
Kirkwood, J. M.
(1991). Intergroup post-operative adjuvant alpha 2 interferon in resected high risk primary and regionally metastatic melanoma. Pittsburgh, PA: Eastern Cooperative Oncology Group.
8.
Kirkwood, J. M.
, Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology, 14(1), 7-17.
Lezak, M. D.
(1995). Neuropsychological assessment(2nd ed.). New York: Oxford University Press.
11.
Matthews, C.
, Cleeland, C., & Hopper, C. L. (1970). Neurological patterns in multiple sclerosis. Archives of Neurology, 34, 556-559.
12.
Mattson, K.
, Niiranen, A., Iivanaiene, M., Farkkila, M., Bergstrom, I., & Holston, I. R. (1983). Neurotoxicity of interferon. Cancer Treatment Reports, 67(10), 958-961.
13.
Meyers, C. A.
, & Abbruzzese, J. L. (1992). Cognitive functioning in cancer patients: Effects of previous treatment. Neurology, 42, 434-436.
14.
Meyers, C. A.
, Scheibel, R. S., & Forman, A. D. (1991). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology, 41, 672-676.
15.
Moertel, C. G.
, Reitemeier, R. J., Bolton, C. F., & Schorter, R. G. (1964). Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemotherapy Reports, 41, 15-18.
16.
Pavol, M. A.
, Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology, 45, 947-950.
17.
Poutiainen, E.
, Hokkanen, L., Niemi, M. L., & Farkkila, M. (1994). Reversible cognitive decline during high-dose alpha-interferon treatment. Pharmacology, Biochemistry, and Behavior, 47(4), 901-905.
18.
Reitan, R. A.
(1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271-276.
19.
Rohatiner, A.Z.S.
, Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983). Central nervous system toxicity of interferon. British Journal of Cancer, 47, 419-422.
20.
Ryan, C. M.
, & Williams, T. M. (1993). Effects of insulin-dependent diabetes on learning and memory efficiency in adults. Journal of Clinical and Experimental Psychology, 15(5), 685-700.
21.
Ryan, C. M.
, Williams, T. M., Orchard, T. J., & Finegold, D. N. (1992). Psychomotor slowing is associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. Diabetes, 41, 107-113.
22.
Schipper, H.
, Clinch, J., Mc Murray, A.,& Levitt, M. (1984). Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. Journal of Clinical Oncology, 2, 472-483.
23.
Silberfarb, P. M.
(1983). Chemotherapy and cognitive deficits in cancer patients. Annual Review of Medicine, 34, 35-46.
24.
Smedley, H.
, Katrak, M., Sikora, K., & Wheeler, T. (1983). Neurological effects of recombinant human interferon. British Medical Journal, 286, 262-264.
25.
Strub, R. L.
, & Black, E. W. (1985). The mental status examination in neurology. Philadelphia: F. A. Davis.
26.
Wechsler, D.
(1981). Manual for the Wechsler Adult Intelligence Scale–Revised. New York: The Psychological Corporation.
27.
Wieneke, M. H.
, & Dienst, E. R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66.
